JANEL CORP (JANL) stock intrinsic value fair value estimate & owner earnings analysis

Janel Corporation is a small holding company with three businesses. Logistics (freight forwarding, customs brokerage, trucking and warehousing for U.S. importers and exporters) is about 90% of revenue and most of the profit. Life Sciences sells research antibodies, diagnostic reagents and lab products, including Biosensis in Australia (bought in 2025), an antibody product line bought from BioPorto A/S on April 8, 2026 for $9.0 million cash plus up to $1.5 million in earnouts, and an antibody royalty stream bought on May 1, 2026. Manufacturing is Indco, a maker of industrial mixers, which Janel now owns outright after buying out the last minority holders on September 29, 2025. On October 14, 2025 Janel moved its Logistics business into Rubicon Technology, a separately listed company, in exchange for new Rubicon shares, and after a tender offer that closed in November 2025 it owns about 91% of Rubicon. So the remaining roughly 9% of Janel's largest business now belongs to Rubicon's other shareholders. How we measured earnings. We start from operating cash flow, take out the large swings in receivables and payables that come with freight billing (in fiscal 2025 a $62.9 million rise in payables inflated reported cash flow, and part of it reversed in the nine months to June 2026), charge stock compensation as a real cost, and deduct the capital spending needed to keep the business running. Amortization of acquired customer lists and product rights (about $2.7 million in fiscal 2025) is added back because it is the accounting write-off of past purchase prices, not a cash cost. Because customer relationships in freight wear away, we do not let the earnings stream last forever (see the cases). We also added back interest and preferred dividends so that we value the whole business first and then subtract everything that ranks ahead of the common shareholders. The starting level is the middle of fiscal 2023 to 2025. Freight is cyclical: prices spiked in fiscal 2021 and 2022 and collapsed in fiscal 2023. We treat the spike as a one-time dislocation and use three years that include a genuine trough (fiscal 2023, about $4.1 million of cash earnings before interest), a normal year (fiscal 2024, $6.7 million) and a strong year (fiscal 2025, $8.9 million, helped by customers shipping early ahead of tariff increases, which the company itself described). The middle year is $6.7 million. We add the full-year contribution of deals that have already closed (Interlog in September 2025, the rest of Biosensis, the BioPorto antibody line and the royalty stream) and subtract Rubicon's added public-company costs, giving about $8.2 million a year, or $6.74 per share. That is about 8% below fiscal 2025's $8.9 million, even though cash earnings grew about 32% in fiscal 2025 (49% per share after interest). We deliberately start lower: the fiscal 2025 jump was partly tariff pull-forward. The nine months to June 30, 2026 ran well ahead of this level. Logistics operating income rose from $6.9 million to $12.4 million on higher volumes in trucking, ocean, air and customs brokerage. But the same period brought tariff turmoil, including $32.0 million of tariff refunds Janel collected for customers and must pass on, and we are not willing to call that the new normal. Life Sciences operating income fell from $2.8 million to $1.3 million over the same nine months, and head-office costs rose. Recent results are mixed, not simply strong. What Janel owes. At June 30, 2026 Janel had $34.6 million of borrowings. That is $13.9 million on a revolving line and $8.8 million of term and mortgage loans under a new Santander and First Merchants facility maturing December 29, 2030, $9.7 million on a second revolving facility maturing December 29, 2027, and $2.2 million of junior subordinated notes owed to related parties. The bank debt floats at about 5.5%, close to our 6% rate, so we made no adjustment for its cost. On top of that come $6.7 million of Series C preferred stock (liquidation value including accrued dividends; the dividend steps up each January toward 9% but Janel can redeem it at any time), $2.7 million to buy out minority owners of Biosensis and Interlog, and $1.5 million of earnouts. The $33.7 million of cash on the balance sheet is almost entirely ($32.0 million) tariff refunds held for customers, so only about $1.7 million counts as Janel's own. Finally, the outside 9% of Rubicon is a claim worth somewhat more than 9% of our business value. Logistics earns more than the consolidated total, because Janel's head-office costs sit outside Rubicon, so that 9% is worth roughly $6 to $15 million depending on the case. Base case, about $40 per share. Cash earnings hold at about $8.2 million a year for ten years. We credit no organic growth, because freight forwarding is competitive and grows with trade volumes rather than through any pricing power we can show. We credit no future acquisitions, because each new deal needs new money and none is signed. After year ten, earnings fade by half over the following twenty years and the story ends in year 30. Forwarding customer lists churn, and nothing we can point to protects them, although Janel's long operating history argues against a quick collapse. The business is worth about $104 million. It owes about $55 million (about $44 million of debt, preferred stock and deal obligations net of its own cash, plus about $11 million belonging to Rubicon's outside shareholders), leaving about $49 million, or $40.16 per share. Bear case, about $7 per share. A freight downturn like fiscal 2023 arrives in the next two years and the tariff-driven pull-forward reverses: cash earnings drop to about $5.5 million for two years and recover only to $6.3 million, as Life Sciences' 2026 decline persists. Earnings fade to zero between years 11 and 20. Janel keeps the preferred stock as its dividend climbs to 9%, which costs about $1.3 million in present value. Interest of roughly $2.4 million a year is still covered about twice, and in a downturn shrinking receivables pay down the revolver, as happened in fiscal 2023. Leverage could still press against the 4.5-times covenant in the new facility. The business is worth about $59 million against about $51 million owed, leaving about $9 million, or $7.05 per share. Bull case, about $63 per share. Part of the strength of the nine months to June 2026 proves durable, and the new antibody lines perform, lifting cash earnings to about $9.8 million. For the first eight years another roughly $0.8 million a year is saved in taxes. In the nine months to June 2026 Janel paid $0.5 million in cash taxes against a $1.3 million tax charge, consistent with Rubicon's accumulated tax losses sheltering Logistics income. Beyond year ten, earnings fade by only a quarter by year 30. The business is worth about $136 million against about $59 million owed, leaving about $77 million, or $63.46 per share. What changed since our previous estimate. Our earlier estimate of $44, $108 and $143 per share valued the business on earnings after interest and did not subtract Janel's bank debt, its preferred stock, its payments owed to minority holders or the Rubicon minority stake. It also assumed earnings would keep growing indefinitely. Taking those claims off the value of the whole business, about $55 million in the base case or roughly $45 per share, is the main reason our estimate is lower. We also cut the long-term story to what we can support: no growth credited and a fade after year ten. Partly offsetting this, the starting level is higher because we now credit the acquisitions closed since fiscal 2025. Margin-of-safety price. With a cyclical, borrowed-against business, a complex ownership chain and a wide gap between the bear and bull cases, the estimate calls for a large margin of safety: the margin-of-safety price is $20, about half the base value. At that price a repeat of fiscal 2023 would hurt but should not be permanent, since in the base case debt is being paid down from about $8 million of yearly cash flow. Could not reconcile: the latest quarterly report does not break out how much of the jump in Logistics profit came from Interlog, from tariff-related customs work or from underlying volume. That is why we did not carry the recent run rate into the base case.